{
  "docId": "019de071-f0b8-737f-9ff6-e8b6f7a1e960",
  "docSlug": "213575480fcc7466657230c6a0d87626",
  "documentTitle": "23andMe | Investor Day Presentation Deck | 78 slides",
  "authorId": "23andme",
  "authorName": "23andMe",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 35,
  "pageCount": 78,
  "prevPage": 34,
  "nextPage": 36,
  "slideType": "other",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 2,
  "notes": "The slide uses heatmaps to visualize genetic associations with various phenotypes, highlighting the CD200R1 pathway.",
  "elementsJson": null,
  "metadataConfidence": 0.9,
  "imagePath": null,
  "slideHref": "/slides/019de071-f0b8-737f-9ff6-e8b6f7a1e960/35",
  "deckHref": "/decks/019de071-f0b8-737f-9ff6-e8b6f7a1e960",
  "deckJsonHref": "/decks/019de071-f0b8-737f-9ff6-e8b6f7a1e960.json",
  "deckAnchorHref": "/decks/019de071-f0b8-737f-9ff6-e8b6f7a1e960#slide-35",
  "components": [
    {
      "bbox": {
        "h": 0.12,
        "w": 0.45,
        "x": 0.5,
        "y": 0.21
      },
      "kind": "callout",
      "text": "CD200R1 pathway identified as a critical immune checkpoint with our I/O genetic signature",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d238ed86-5503-4c2a-8a2e-824742d2f133",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.25,
        "x": 0.56,
        "y": 0.4
      },
      "kind": "chart",
      "text": "Comparison of CD200R1, CD200, and DOK2 genetic signatures",
      "attrs": null,
      "subkind": "bar-stacked",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f9458de4-5c5d-40ab-bf3c-f48f3d329202",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.28,
        "x": 0.12,
        "y": 0.28
      },
      "kind": "chart",
      "text": "Heatmap showing genetic associations with immune/autoimmune and cancer phenotypes",
      "attrs": null,
      "subkind": "heatmap",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7bc475dc-42ea-430f-aacc-99201aa7fc0f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.45,
        "x": 0.5,
        "y": 0.82
      },
      "kind": "paragraph",
      "text": "We discovered that 3 components of the signaling pathway for CD200R1 have a similar genetic signature to other I/O drugs",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "966a993e-f8aa-4479-8680-731df9c8a49f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "CD200R1 was Identified as a Promising Anti-Cancer Drug Target with 23andMe’s Proprietary Immuno-oncology (I/O) Genetic Signature",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4a09f858-af85-422b-b2a9-f61033e7e2fe",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 42,
      "from": 33,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "934e5ad9-c4e2-4bad-8ae5-f1cb9185ca0d",
      "evidence": "The presentation deck presents data and research findings on 23ME-00610, a novel immuno-oncology antibody targeting CD200R1",
      "position": 1,
      "objective": "Can 23andMe's immuno-oncology antibody targeting CD200R1 provide a quick win in cancer treatment?",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.7,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}